103 related articles for article (PubMed ID: 34169913)
1. Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19.
Vityala Y; Tagaev T; Mamatov S; Aidarov Z; Harinath P
Indian J Pharmacol; 2021; 53(3):246-247. PubMed ID: 34169913
[No Abstract] [Full Text] [Related]
2. Serum Concentrations of Interleukin 6 in the General Adult Population: Possible Implications for Anti-IL-6 Therapy in SARS-Cov-2 Infection and IL-6-Related Diseases.
Alende-Castro V; Alonso-Sampedro M; Gude F; Gonzalez-Quintela A
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):75-78. PubMed ID: 32500858
[No Abstract] [Full Text] [Related]
3. The shortcomings of tocilizumab in COVID-19.
Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
[TBL] [Abstract][Full Text] [Related]
4. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19.
Guirao JJ; Cabrera CM; Jiménez N; Rincón L; Urra JM
Mol Immunol; 2020 Dec; 128():64-68. PubMed ID: 33075636
[TBL] [Abstract][Full Text] [Related]
5. Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer.
Portsmore S; Tran Nguyen TN; Beacham E; Neelakantan P
Br J Haematol; 2020 Aug; 190(4):525-528. PubMed ID: 32584421
[No Abstract] [Full Text] [Related]
6. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
7. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
8. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A
Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
[No Abstract] [Full Text] [Related]
10. Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
Strohbehn GW; Reid PD; Ratain MJ
Clin Pharmacol Ther; 2020 Sep; 108(3):425-427. PubMed ID: 32488861
[TBL] [Abstract][Full Text] [Related]
11. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.
Widysanto A; Kurniawan A; Lugito NPH; Yuniarti M; Gunawan C; Angela ; Wiryanto J; Levinna ; Pradhana TM
Cytokine; 2021 Feb; 138():155393. PubMed ID: 33333393
[TBL] [Abstract][Full Text] [Related]
12. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City.
Maeda T; Obata R; Rizk DO D; Kuno T
J Med Virol; 2021 Jan; 93(1):463-471. PubMed ID: 32720702
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
Innes AJ; Cook LB; Marks S; Bataillard E; Crossette-Thambiah C; Sivasubramaniam G; Apperley J; Milojkovic D
Br J Haematol; 2020 Aug; 190(4):e198-e200. PubMed ID: 32593183
[No Abstract] [Full Text] [Related]
14. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
[TBL] [Abstract][Full Text] [Related]
15. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.
Quartuccio L; Sonaglia A; Pecori D; Peghin M; Fabris M; Tascini C; De Vita S
J Med Virol; 2020 Nov; 92(11):2852-2856. PubMed ID: 32515499
[TBL] [Abstract][Full Text] [Related]
16. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
Antony SJ; Davis MA; Davis MG; Almaghlouth NK; Guevara R; Omar F; Del Rey F; Hassan A; Arian MU; Antony N; Prakash BV
J Med Virol; 2021 Jan; 93(1):491-498. PubMed ID: 32644254
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
18. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
Mantero V; Rigamonti A; Basilico P; Crespi M; Balgera R; Salmaggi A
J Neurol; 2020 Dec; 267(12):3465-3466. PubMed ID: 32638109
[No Abstract] [Full Text] [Related]
19. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
[TBL] [Abstract][Full Text] [Related]
20. Availability of drugs for severe COVID-19 in sub-Saharan Africa.
Njonnou SRS; Ouankou CN; Lekpa FK; Balti EV; Choukem SP
Pan Afr Med J; 2020; 35(Suppl 2):48. PubMed ID: 33623573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
